Decreased purinergic inhibition of synaptic activity in a mouse model of Niemann-Pick disease type C
- PMID: 20082288
- DOI: 10.1002/hipo.20741
Decreased purinergic inhibition of synaptic activity in a mouse model of Niemann-Pick disease type C
Abstract
Niemann-Pick disease type C (NPC) is a progressive neurodegenerative disorder characterized by accumulation of free cholesterol in lysosomes, mainly due to a mutation in the NPC1 gene. The pathophysiological basis of the neural disorders in NPC, however, is not well understood. We found that the hippocampal field excitatory postsynaptic potential (fEPSP) was enhanced in NPC1 mutant mice. A1-receptor antagonist or adenosine degrading enzyme enhanced the fEPSP in both types of mice, but had a much weaker effect in the mutant mice, suggesting less tonic inhibition of synaptic transmission by endogenous adenosine in the mutant. Further evidence showed impaired hippocampal long term potentiation (LTP) in mutant mice. Supplement of A1 agonist N6-Cyclopentyladenosine (CPA) partially rescued the impaired LTP in mutant mice. Moreover, adenosine release from hippocampal slices was significantly decreased in the mutant. The enhanced excitatory synaptic transmission and the decreased synaptic plasticity due to the decreased adenosine release in NPC brain may partially contribute to the neural disorders of NPC disease, such as seizures, neurodegeneration, and dementia.
Copyright © 2009 Wiley-Liss, Inc.
Similar articles
-
Glutamatergic neurotransmission in a mouse model of Niemann-Pick type C disease.Brain Res. 2011 Jun 17;1396:11-9. doi: 10.1016/j.brainres.2011.04.020. Epub 2011 Apr 19. Brain Res. 2011. PMID: 21575932
-
Defects of synaptic vesicle turnover at excitatory and inhibitory synapses in Niemann-Pick C1-deficient neurons.Neuroscience. 2010 May 19;167(3):608-20. doi: 10.1016/j.neuroscience.2010.02.033. Epub 2010 Feb 16. Neuroscience. 2010. PMID: 20167265
-
Pathological cholesterol metabolism fails to modify electrophysiological properties of afflicted neurones in Niemann-Pick disease type C.Neuroscience. 2005;130(4):867-73. doi: 10.1016/j.neuroscience.2004.09.065. Neuroscience. 2005. PMID: 15652985
-
Niemann-Pick Disease Type C: from molecule to clinic.Clin Exp Pharmacol Physiol. 2010 Jan;37(1):132-40. doi: 10.1111/j.1440-1681.2009.05235.x. Epub 2009 Jun 29. Clin Exp Pharmacol Physiol. 2010. PMID: 19566836 Review.
-
[Advances in elucidating the pathophysiology and targeting therapy to treat Niemann-Pick type C disease].No To Hattatsu. 2010 Mar;42(2):92-102. No To Hattatsu. 2010. PMID: 23858590 Review. Japanese. No abstract available.
Cited by
-
Long-Term Potentiation at CA3-CA1 Hippocampal Synapses with Special Emphasis on Aging, Disease, and Stress.Front Aging Neurosci. 2011 May 20;3:7. doi: 10.3389/fnagi.2011.00007. eCollection 2011. Front Aging Neurosci. 2011. PMID: 21647396 Free PMC article.
-
Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat.Genes (Basel). 2024 Feb 25;15(3):290. doi: 10.3390/genes15030290. Genes (Basel). 2024. PMID: 38540351 Free PMC article. Review.
-
Plasma membrane remodeling in GM2 gangliosidoses drives synaptic dysfunction.PLoS Biol. 2025 Jul 3;23(7):e3003265. doi: 10.1371/journal.pbio.3003265. eCollection 2025 Jul. PLoS Biol. 2025. PMID: 40608809 Free PMC article.
-
Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin.J Lipid Res. 2014 Aug;55(8):1609-21. doi: 10.1194/jlr.R047837. Epub 2014 Mar 24. J Lipid Res. 2014. PMID: 24664998 Free PMC article. Review.
-
New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease.Sci Rep. 2017 Feb 7;7:41931. doi: 10.1038/srep41931. Sci Rep. 2017. PMID: 28167839 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical